Skip to content

    Lung Cancer Health Center

    Font Size
    A
    A
    A

    Non-Small Cell Lung Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage IIIA NSCLC Treatment

    continued...

    As referred to in the National Cancer Institute of Canada and Intergroup Study JBR.10 study (NCT00002583), PORT may be considered in selected patients to reduce the risk of local recurrence, if any of the following are present:[13]

    • Involvement of multiple nodal stations.
    • Extracapsular tumor spread.
    • Close or microscopically positive resection margins.

    Evidence (adjuvant radiation therapy):

    Evidence from one large meta-analysis, subset analyses of randomized trials, and one large population study suggest that PORT may reduce local recurrence. Results from these studies on the effect of PORT on OS are conflicting.

    1. A meta-analysis of ten randomized trials that evaluated PORT versus surgery alone showed the following:
      • No difference in OS for the entire PORT group or for the subset of N2 patients.[8][Level of evidence: 1iiA]
    2. Results from a nonrandomized subanalysis of the ANITA trial, comparing 5-year OS in N2 patients who did or did not receive PORT, found the following:[4]
      • Higher survival rates in patients receiving radiation therapy in both the observation and chemotherapy arms (21% vs. 17% and 47% vs. 34%, respectively [statistical tests of comparison were not conducted]).[4]
    3. Results from the Surveillance, Epidemiology, and End Results (SEER) [15] suggest the following:
      • The large SEER retrospective study (N = 7,465) found superior survival rates associated with radiation therapy in N2 disease (HR, 0.855; 95% CI, 0.762-0.959).

    There is benefit of PORT in stage IIIA-N2 disease, and the role of PORT in early stages of NSCLC should be clarified in ongoing phase III trials. Further analysis is needed to determine whether these outcomes can be modified with technical improvements, better definitions of target volumes, and limitation of cardiac volume in the radiation portals.[8]

    Standard Treatment Options for Unresectable Stage IIIA N2 NSCLC

    Standard treatment options for patients with unresectable NSCLC include the following:

    1. Radiation therapy.
      • For treatment of locally advanced unresectable tumor in patients who are not candidates for chemoradiation therapy.
      • For patients requiring palliative treatment.
    2. Chemoradiation therapy.

    Radiation therapy

    For treatment of locally advanced unresectable tumor

    Radiation therapy alone, administered sequentially with chemotherapy and concurrently with chemotherapy, may provide benefit to patients with locally advanced unresectable stage III NSCLC.

    1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
    1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
    Next Article:

    Today on WebMD

    Xray analysis
    Do you know the myths from the facts?
    chest x-ray
    Get to know them.
     
    woman taking pills
    Tips to managing them.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    Lung Cancer Risks Myths and Facts
    SLIDESHOW
    Woman getting ct scan
    Article
     
    Improving Lung Cancer Survival Targeted Therapy
    VIDEO
    cancer fighting foods
    Article
     
    Lung Cancer Surprising Differences Between Sexes
    VIDEO
    Pets Improve Your Health
    SLIDESHOW
     
    Vitamin D
    SLIDESHOW
    Lung Cancer Surgery Options
    VIDEO